Brief: Provectus Announces Presentation Of Updated Results From Phase 1B Trial Of Pv-10 In Combination With Keytruda (Pembrolizumab)
25/10/2018 13:11
Oct 25 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM
PHASE
1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB)
FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
Source text for Eikon: ID:nGNXc74tW5
Further company coverage: PVCT.PK
((Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting